Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

1.49
-0.2610-14.91%
Volume:679.16K
Turnover:1.01M
Market Cap:5.31M
PE:-0.31
High:1.58
Open:1.49
Low:1.42
Close:1.75
52wk High:14.64
52wk Low:1.42
Shares:3.57M
Float Shares:3.22M
Volume Ratio:0.17
T/O Rate:21.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:1.30
PE(LYR):-0.22

Loading ...

Cadrenal Therapeutics Inc - to Advance Directly to Phase 3 Study of CAD-1005 in Hit

THOMSON REUTERS
·
Apr 30

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting With the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (Hit)

THOMSON REUTERS
·
Apr 30

Cadrenal Therapeutics Inc - Phase 2 Data Shows >25% Absolute Reduction in Thrombotic Events With CAD-1005

THOMSON REUTERS
·
Apr 30

BRIEF-Cadrenal Therapeutics Inc - Prospectus Filed For Resale Of Up To 1.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing

Reuters
·
Apr 21

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

TIPRANKS
·
Apr 21

Cadrenal Therapeutics Inc - Prospectus Filed for Resale of up to 1.2 Mln Shares of Common Stock by Selling Stockholders- SEC Filing

THOMSON REUTERS
·
Apr 21

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:43 AM

Reuters
·
Apr 17

U.S. RESEARCH ROUNDUP-3M, CME Group, TransDigm Group

Reuters
·
Apr 08

Cadrenal Therapeutics Inc : H.c. Wainwright Cuts Target Price to $13 From $32

THOMSON REUTERS
·
Apr 08

Cadrenal Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Apr 02

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:29 PM

Reuters
·
Apr 02

Noble Financial Remains a Buy on Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
Apr 01

Cadrenal Therapeutics warrant holder exercises 571,430 warrants, generating $2.5 million proceeds

Reuters
·
Apr 01

FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk

TIPRANKS
·
Apr 01

Cadrenal Therapeutics FY25 net loss widens to $13.2 million

Reuters
·
Apr 01

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for Hit Following End-of-Phase 2 FDA Meeting

THOMSON REUTERS
·
Mar 31

Cadrenal highlights Phase 2 trial data showing CAD-1005 reduced thrombotic events in suspected HIT patients

Reuters
·
Mar 12

Cadrenal Therapeutics Highlights Research Supporting 12-Lox Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Mar 12

Cadrenal Therapeutics Inc expected to post a loss of $1.16 a share - Earnings Preview

Reuters
·
Mar 10